chartexchange

Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates

GlobeNewswire Inc. | Nov 6, 2026 9:00 AM EST

  Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027

Read original article